In the three months to the end of June, net profit fell to $38.8 million from $42 million a year earlier. In the first half, however, earnings were up 25% to $101.6 million.
GAAP EPS was 60 cents compared to 66 cents in the prior year. On a non-GAAP basis, net income attributable to Iconix was $39.6 million, or 75 cents share, for the quarter. That beat analysts estimate for 67 cents a share.
Sales in the quarter were up 3% to $118.9 million, and in the six month period were up 7% to $235.1 million.
CEO Neil Cole, said: “With record results in the second quarter, we continue to demonstrate the power of our business model with our diversified revenue stream and strong free cash flow. As we look to the future we believe we can continue to deliver significant growth and increased value for our company and shareholders through our global expansion plans … and additional acquisitions of global iconic brands.”
For the full year, Iconix has raised its non-GAAP diluted EPS guidance to $2.60 to $2.70 from $2.55 to $2.65. Revenue guidance is now in the range of $455 million to $465 million from its previous forecast of $450 million to $460 million.
For commercial purposes, extract supplements can be obtained from the fruit of the pericarp. Garcinia cambogia reviews is performed by a physician Chen and Oz to prove that it is an herb for weight loss, a lot of research has been done. Studies, Garcinia cambogia extract supplementation decreases the weight of the body fat accumulation, was shown to have a positive effect on prevention. We are important substances such as cholesterol (LDL), reduces the serum leptin and triglycerides. In addition, it will increase the level of serotonin and cholesterol (HDL). The study also, Garcinia cambogia extract supplements, has proven that there are no significant adverse effects on many of the eight weeks, such as its use.